AR070911A1 - USE OF PARTA RECEPTOR ANTAGONISTS ACTIVATED WITH PROTEASA - Google Patents

USE OF PARTA RECEPTOR ANTAGONISTS ACTIVATED WITH PROTEASA

Info

Publication number
AR070911A1
AR070911A1 ARP090100937A ARP090100937A AR070911A1 AR 070911 A1 AR070911 A1 AR 070911A1 AR P090100937 A ARP090100937 A AR P090100937A AR P090100937 A ARP090100937 A AR P090100937A AR 070911 A1 AR070911 A1 AR 070911A1
Authority
AR
Argentina
Prior art keywords
pain
par2
antagonist
fracture
inhibitor
Prior art date
Application number
ARP090100937A
Other languages
Spanish (es)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of AR070911A1 publication Critical patent/AR070911A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Uso de un antagonista del receptor 2 activado con proteasa (PAR2) para el tratamiento del dolor que incluye el dolor postoperatorio en una incision, el dolor neuropático, el dolor por fractura, el dolor por fractura osteoporotica, el dolor por cáncer de hueso o el dolor articular por gota; el dolor inflamatorio asociado con el síndrome de colon irritable; y la inflamacion relacionada con la artritis reumatoide o la osteoartritis, el antagonista de PAR2 es un anticuerpo anti-PAR2 humano o un fragmento de un anticuerpo que se une al antígeno. Reivindicacion 6: Uso de un antagonista del receptor 2 activado con proteasa (PAR2) segun las reivindicaciones 4 o 5, y uno o varios agentes terapéuticos adicionales seleccionados a partir de otro antagonista de PAR2, un inhibidor de citocina, un fármaco antiepiléptico, un inhibidor de NGF, una colchicina, un fármaco anti-inflamatorio no esteroideo (NSAID), un corticoesteroide y un inhibidor de TNF, en la preparacion de un medicamento para tratar, inhibir o aliviar el dolor asociado con la inflamacion, el dolor postoperatorio en una incision, la neuropatía, la fractura de huesos, la fractura osteoporotica, el cáncer de hueso o la gota.Use of a protease activated receptor 2 (PAR2) antagonist for the treatment of pain that includes postoperative pain in an incision, neuropathic pain, fracture pain, osteoporotic fracture pain, bone cancer pain or joint pain from gout; inflammatory pain associated with irritable bowel syndrome; and inflammation related to rheumatoid arthritis or osteoarthritis, the PAR2 antagonist is a human anti-PAR2 antibody or a fragment of an antibody that binds to the antigen. Claim 6: Use of a protease activated receptor 2 (PAR2) antagonist according to claims 4 or 5, and one or more additional therapeutic agents selected from another PAR2 antagonist, a cytokine inhibitor, an antiepileptic drug, an inhibitor of NGF, a colchicine, a non-steroidal anti-inflammatory drug (NSAID), a corticosteroid and a TNF inhibitor, in the preparation of a medication to treat, inhibit or relieve pain associated with inflammation, postoperative pain in an incision , neuropathy, bone fracture, osteoporotic fracture, bone cancer or gout.

ARP090100937A 2008-03-19 2009-03-16 USE OF PARTA RECEPTOR ANTAGONISTS ACTIVATED WITH PROTEASA AR070911A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3790808P 2008-03-19 2008-03-19
US11915508P 2008-12-02 2008-12-02

Publications (1)

Publication Number Publication Date
AR070911A1 true AR070911A1 (en) 2010-05-12

Family

ID=40718925

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100937A AR070911A1 (en) 2008-03-19 2009-03-16 USE OF PARTA RECEPTOR ANTAGONISTS ACTIVATED WITH PROTEASA

Country Status (6)

Country Link
AR (1) AR070911A1 (en)
CL (1) CL2009000660A1 (en)
PE (1) PE20091693A1 (en)
TW (1) TW201002345A (en)
UY (1) UY31723A (en)
WO (1) WO2009117481A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214655B2 (en) * 2001-05-21 2007-05-08 Johnson & Johnson Consumer Companies, Inc. Peptides and the use thereof in darkening the skin
US7888482B2 (en) 2006-02-10 2011-02-15 Amgen Inc. Antibodies that bind PAR-2
JO3246B1 (en) 2009-09-09 2018-03-08 Regeneron Pharma High affinity human antibodies to human protease-activated receptor-2
WO2013064583A1 (en) 2011-11-04 2013-05-10 Lipotec, S.A. Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
WO2015048245A1 (en) 2013-09-25 2015-04-02 Vertex Pharmaceuticals Incorporated Imidazopyridazines useful as inhibitors of the par-2 signaling pathway
US20160000791A1 (en) 2014-07-07 2016-01-07 Mayo Foundation For Medical Education And Research Par1 modulation to alter myelination
CA3024719A1 (en) * 2016-05-20 2017-11-23 Takeda Pharmaceutical Company Limited Treatment of pain
US20190201454A1 (en) * 2016-06-23 2019-07-04 Mayo Foundation For Medical Education And Research Par2 modulation to alter myelination
TWI788332B (en) * 2017-03-16 2023-01-01 英商梅迪繆思有限公司 Anti-par2 antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629174A (en) * 1993-07-26 1997-05-13 Cor Therapeutics, Inc. Recombinant C140 receptor
NZ334998A (en) * 1995-01-25 2000-11-24 Cor Therapeutics Inc Use of an agonist or antagonist for inhibiting the expression of a C140 receptor
WO2005123193A2 (en) * 2004-06-17 2005-12-29 Osteologix A/S Treatments comprising strontium for rheumatic and arthritic diseases and pain

Also Published As

Publication number Publication date
WO2009117481A1 (en) 2009-09-24
PE20091693A1 (en) 2009-11-16
TW201002345A (en) 2010-01-16
UY31723A (en) 2009-11-10
CL2009000660A1 (en) 2010-04-16

Similar Documents

Publication Publication Date Title
AR070911A1 (en) USE OF PARTA RECEPTOR ANTAGONISTS ACTIVATED WITH PROTEASA
Cao et al. Pharmacotherapy for knee osteoarthritis: current and emerging therapies
Ghouri et al. Update on novel pharmacological therapies for osteoarthritis
Robinson et al. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis
Oo et al. The development of disease-modifying therapies for osteoarthritis (DMOADs): the evidence to date
Oo et al. Disease-modifying drugs in osteoarthritis: current understanding and future therapeutics
Rosero et al. Preemptive, preventive, multimodal analgesia: what do they really mean?
Bigoni et al. Acute and late changes in intraarticular cytokine levels following anterior cruciate ligament injury
Yang et al. Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial
Ghosh et al. Treatment of acute gouty arthritis in complex hospitalized patients with anakinra
Adami et al. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial
Ominsky et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones
Baltzer et al. Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis
Grossman Lupus arthritis
Watt et al. New drug treatments for osteoarthritis: what is on the horizon?
CY1118044T1 (en) COMPOSITION PREPARATION WITH COMPETITOR AND CORTICOSTEROIDS
Chen et al. Arthrofibrosis and large joint scarring
BRPI0611984A2 (en) use of igf-ir antibodies to manufacture a drug to treat a bone tumor
Altman Pharmacological therapies for osteoarthritis of the hand: a review of the evidence
PE20071221A1 (en) GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS
AR039656A1 (en) USE OF ANTI-TNF ALFA AND OTHER PHARMACO ANTIBODIES
CL2007003094A1 (en) DISCONTINUOUS CRYSTALLIZATION METHOD FOR CRYSTALLIZING AN ANTI-FACTOR ANTIBODY OF HUMAN ALPHA TUMOR NECROSIS (TNF ALFA); ANTIBODY CRYSTAL; PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT; AND ITS USE TO TREAT DISEASES RELATED TO TNF ALFA
Trueba Davalillo et al. Clinical efficacy of intra-articular injections in knee osteoarthritis: a prospective randomized study comparing hyaluronic acid and betamethasone
Wu et al. High-molecular-weight hyaluronic acid attenuated matrix metalloproteinase-1 and-3 expression via CD44 in tendinopathy
Zufferey et al. Efficacy of anakinra in acute hydroxyapatite calcification-induced joint pain: a retrospective study of 23 cases

Legal Events

Date Code Title Description
FB Suspension of granting procedure